-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: U.S. Patent and Trademark Office
USPTO Blogpost Brings Mayo Down to Earth
The United States Patent and Trademark Office Director David Kappos posted a blogpost called “Some Thoughts on Patentability” which discusses a recent Federal Circuit decision in CLS Bank International v. Alice Corporation and the lessons we should learn from the Federal Circuit. “Based on my experience, I appreciate the wisdom of the court’s discussion relating to resolving disputed claims by focusing initially on patentability requirements of § 102, 103, and 112, rather than § 101. Read More >
Exclusive Licenses Do Not Discourage Follow On Research
A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions. First, does exclusive licensing affect licensee follow-on research? Read More >
The Critical Importance of International Patent Protection for Small Businesses
As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection. Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >
BIO Joins 261 Business, Research Institutions and Organizations to Urge Caution in Microsoft v. i4i Case*
*UPDATE – 90 more organizations have decided to add their names to the letter sent to the Department of Justice. Please find the new letter. Please find attached an open letter to Attorney General Holder and Acting Solicitor General Katyal, signed by 171 businesses, research institutions and organizations of all sizes, representing U.S. innovation in all 50 states and the District of Columbia. The signatories include leading innovators in agriculture, biotechnology, consumer products, electrical, mechanical and Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: Acting Solicitor General Katyal, Attorney General Holder, BIO, clear and convincing evidence, i4i, Microsoft, Microsoft v. i4i, patent, Patent Reform, patents, preponderance standard, Supreme Court, U.S. Department of Justice, U.S. Patent and Trademark Office, USPTO
Tags: Acting Solicitor General Katyal, Attorney General Holder, BIO, clear and convincing evidence, i4i, Microsoft, Microsoft v. i4i, patent, Patent Reform, patents, preponderance standard, Supreme Court, U.S. Department of Justice, U.S. Patent and Trademark Office, USPTO
BIO’s Comments on proposed PTO Humanitarian Technologies and Licensing Through the Intellectual Property System
Here are the highlights from BIO’s recent submission on the proposed PTO “Request for Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System.” Background: 1. “BIO’s members also understand that problems with access to medicines and other biotechnology products in the developing world have very little to do with the patent system, and are generally caused by other factors outside the control of individual stakeholders, such as lack of adequate local manufacturing, Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: access to medicines, BIO, BIOTECH, biotechnology, Biotechnology Industry Organization, developing countries, economic development, Global Health, Green Technology, humanitarian, humanitarian technologies, International, Patent and Trademark Office, Patent Reform, patents, poverty, PTO, re-examination vouchers, U.S. Patent and Trademark Office, United States Patent and Trademark Office, USPTO
Tags: access to medicines, BIO, BIOTECH, biotechnology, Biotechnology Industry Organization, developing countries, economic development, Global Health, Green Technology, humanitarian, humanitarian technologies, International, Patent and Trademark Office, Patent Reform, patents, poverty, PTO, re-examination vouchers, U.S. Patent and Trademark Office, United States Patent and Trademark Office, USPTO
